Apostolidis Leonidas, Kahlert Christoph, Siegmund Annika, Thom Rabea, Horstmann Solveig, Jäger Dirk, Lordick Florian
Department of Medical Oncology, National Center for Tumor Diseases, Universität Heidelberg, Im Neuenheimer Feld 350, Heidelberg, Germany.
Onkologie. 2009 Feb;32(1-2):50-3. doi: 10.1159/000183750. Epub 2009 Jan 19.
Hepatocellular carcinoma (HCC) is one of the most common tumor diseases worldwide. Dermatomyositis is a known paraneoplastic syndrome that can complicate the course of a variety of different cancers, however, the association with HCC is extremely rare.
Here, we report on a patient with the rare concurrence of dermatomyositis and non-hepatitis-associated advanced HCC with intra-abdominal and intrathoracal lymph node metastases. The HCC was treated with sorafenib. The dermatomyositis responded well to treatment with prednisolone and azathioprin although sorafenib did not lead to a response in the underlying HCC.
Paraneoplastic dermatomyositis can be associated with non-hepatitis-associated HCC. The potential pathogenetic links between these two diseases are discussed, as well as a potential immunomodulatory effect of sorafenib independent of its antineoplastic potential.
肝细胞癌(HCC)是全球最常见的肿瘤疾病之一。皮肌炎是一种已知的副肿瘤综合征,可使多种不同癌症的病程复杂化,然而,与HCC的关联极为罕见。
在此,我们报告一例罕见的皮肌炎与非肝炎相关性晚期HCC并发,并伴有腹腔和胸腔内淋巴结转移的患者。该HCC患者接受了索拉非尼治疗。尽管索拉非尼对潜在的HCC无反应,但皮肌炎对泼尼松龙和硫唑嘌呤治疗反应良好。
副肿瘤性皮肌炎可与非肝炎相关性HCC相关。讨论了这两种疾病之间潜在的发病机制联系,以及索拉非尼独立于其抗肿瘤潜力的潜在免疫调节作用。